H.C. Wainwright initiates coverage of Ardelyx (ARDX) stock with a "Buy" rating

From Yahoo Finance: 2025-06-25 13:01:00

H.C. Wainwright began coverage on Ardelyx, Inc. stock (ARDX) with a “Buy” rating and $10.00 price objective, praising the company’s successful bowel and kidney disease treatments.

Ardelyx, Inc. showcased strong Q1 2025 performance, with $74 million in revenue, driven by IBSRELA and XPHOZAH sales. IBSRELA saw 57% YoY growth, with $44.4 million in net product sales revenue.

Ardelyx, Inc. focuses on developing and commercializing medicines for unmet medical needs, demonstrating significant potential for growth and commercial success in the near term.

For those seeking promising AI stocks with 100x upside potential, consider alternatives to ARDX. Explore our report on the cheapest AI stock for higher returns.

Explore more investment opportunities with 13 Cheap AI Stocks to Buy and 11 Unstoppable Growth Stocks to Invest in Now. Disclosure: None.

Read more: H.C. Wainwright Initiates Coverage of Ardelyx (ARDX) Stock, Gives Buy